Exploratory cost-effectiveness analysis of 68 Gallium-PSMA PET/MRI-based imaging in patients with biochemical recurrence of prostate cancer
AbstractMen treated for prostate cancer with curative intent face a recurrence rate of up to 53% at 10 years.68Ga-PSMA imaging is a new technique that can more accurately stage cancer recurrences and facilitate personalised treatment. We evaluated the cost-effectiveness of68Ga-PSMA PET/MRI for staging men with prostate cancer biochemical recurrence. A cost-effectiveness analysis using a decision-analytic model with Markov chains was constructed.68Ga-PSMA PET/MRI was compared with usual care in staging of men with suspected prostate cancer recurrence. Men with biochemical recurrence from a study in Brisbane, Australia (n = 30) provided key estimates for the model. The primary outcomes were health system costs and years of life (survival) over 10 years. Deterministic and probabilistic sensitivity analyses were undertaken to address uncertainty in model estimates. On average, a strategy of68Ga-PSMA was expected to cost AU$56 961(US$39 426) and produce 7.48 life years compared with AU$64 499 (US$44 667) and 7.41 life years in usual care. Therefore,68Ga-PSMA was potentially cost saving ( − AU$7 592 95% UI − $24 846, $7 825) (− US$5 258) and slightly more effective 0.07 life years (95% UI − 0.01, 0.16). The likelihood that68Ga-PSMA strategy was cost-effective at acceptable thresholds was 87%. The findings were sensitive to the lesion detection rate of the68Ga-PSMA strategy (52 –75%) and the cost of follow up in usual care (AU$...
Publication date: Available online 2 April 2020Source: Urology Case ReportsAuthor(s): Takashi Ando, Kazuhiro Watanabe, Takaki Mizusawa, Takeshi Sakai, Akiyoshi Katagiri
Publication date: Available online 2 April 2020Source: Urology Case ReportsAuthor(s): Alexandar Blazevski, Amer Amin, Gordon O'Neill
Publication date: Available online 2 April 2020Source: Respiratory Medicine Case ReportsAuthor(s): Caibao Jin, Hui Ren, Yang Hu, Jingyi Wu, Yanping Hu, Zhijun Wang, Youying Wei, Bin Yang, Ling Yang
Condition: Metastatic Prostate Cancer Interventions: Drug: Enzalutamide; Drug: Talazoparib Sponsors: MedSIR; Pfizer Not yet recruiting
Conclusion: We report the efficacy and safety of IFX maintained for up to 12 years in psoriasis patients. The long-term use of IFX was associated with a high BMI confirming the critical role of weight-based dosing for this drug. PMID: 32231699 [PubMed]
Madam — Docetaxel chemotherapy may be offered to patients with high-risk, hormone-sensitive non-metastatic prostate cancer alongside neoadjuvant androgen deprivation therapy (nADT) prior to treatment with radiotherapy . Prostate-specific antigen (PSA) levels monitor treatment response and fall with n ADT and radiotherapy. Pre-radiotherapy PSA levels measured after nADT have shown some value as a prognostic marker; pre-radiotherapy nadir PSA
In this study, a unique experimental set-up consisting of a Raman microscope, coupled with a commercial shear-flow microfluidic system is used to monitor fatty acid uptake by prostate cancer (PC-3) cells in real-time at the single cell level. Uptake of deuterated PA, deuterated AA, and the omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) were monitored using this new system, while complementary flow cytometry experiments using Nile red staining, were also conducted for the validation of the cellular lipid uptake. Using this novel experimental system, we show that DHA and EPA have inhibitory ef...
ConclusionsThis study confirms PIRADS has high accuracy, sensitivity and NPV for detecting all CaP and csCaP. A high NPV may obviate need for biopsy in low ‐risk patients.
In conclusion, the combination of ionizing radiation and oncolytic adenovirus expressing IL24 could achieve synergistic anti-tumor effect on prostate cancer, and is a promising strategy for prostate cancer therapy.
Purpose: Late gastrointestinal (GI) toxicity after radiotherapy for prostate cancer may have significant impact on the cancer survivor's quality of life. To date, little is known about local dose-effects after modern radiotherapy including hypofractionation. In the current study we related the local spatial distribution of radiation dose in the rectum to late patient-reported gastrointestinal (GI) toxicities for conventionally fractionated (CF) and hypofractionated (HF) modern radiotherapy in the randomized HYPRO trial.Material and Methods: Patients treated to 78 Gy in 2 Gy fractions (n = 298) or 64.6 Gy in 3.4 Gy fraction...